Acne Vulgaris Clinical Trial
Official title:
A Phase 3 Multi-Center, Open Label Study Evaluating the Long Term Safety of SB204 Once Daily in the Treatment of Acne Vulgaris
| Verified date | May 2023 |
| Source | Novan, Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.
| Status | Completed |
| Enrollment | 601 |
| Est. completion date | April 27, 2017 |
| Est. primary completion date | April 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 9 Years to 99 Years |
| Eligibility | Inclusion Criteria: - Have completed 12 weeks of treatment in NI-AC301 or NI-AC302 Exclusion Criteria: - Terminated early from an SB204 Phase 3 pivotal study for any reason - Have an on-going adverse event at Week 12 visit for NI-AC301 or NI-AC302 that warrants stopping study drug application - Have used medications or vitamins during the 12 weeks immediately preceding this study which were reported to exacerbate acne. |
| Country | Name | City | State |
|---|---|---|---|
| United States | CIL #156 | Albuquerque | New Mexico |
| United States | CIL #146 | Anaheim | California |
| United States | CIL #198 | Arlington | Texas |
| United States | CIL #160 | Austin | Texas |
| United States | CIL #154 | Beaumont | Texas |
| United States | CIL #201 | Berlin | New Jersey |
| United States | CIL #138 | Birmingham | Alabama |
| United States | CIL #103 | Boca Raton | Florida |
| United States | CIL #137 | Broomall | Pennsylvania |
| United States | CIL #184 | Bryan | Texas |
| United States | CIL #139 | Cerritos | California |
| United States | CIL #217 | Chattanooga | Tennessee |
| United States | CIL #216 | Chula Vista | California |
| United States | CIL #169 | Cincinnati | Ohio |
| United States | CIL #226 | Cincinnati | Ohio |
| United States | CIL #186 | Fresno | California |
| United States | CIL #210 | Fresno | California |
| United States | CIL #237 | Gresham | Oregon |
| United States | CIL #208 | Hialeah | Florida |
| United States | CIL #212 | Homestead | Florida |
| United States | CIL #188 | Houston | Texas |
| United States | CIL #174 | Huntington Beach | California |
| United States | CIL #213 | La Mesa | California |
| United States | CIL #182 | Las Vegas | Nevada |
| United States | CIL #222 | Lauderdale Lakes | Florida |
| United States | CIL #117 | Louisville | Kentucky |
| United States | CIL #105 | Lynchburg | Virginia |
| United States | CIL #170 | Miami Lakes | Florida |
| United States | CIL #204 | Miami Springs | Florida |
| United States | CIL #218 | Mobile | Alabama |
| United States | CIL #219 | Monroe | Louisiana |
| United States | CIL #141 | Montclair | New Jersey |
| United States | CIL #175 | New Albany | Indiana |
| United States | CIL #116 | Newnan | Georgia |
| United States | CIL #148 | Norfolk | Nebraska |
| United States | CIL #231 | Norfolk | Virginia |
| United States | CIL #209 | Oceanside | California |
| United States | CIL #140 | Omaha | Nebraska |
| United States | CIL #172 | Orlando | Florida |
| United States | CIL #185 | Ormond Beach | Florida |
| United States | CIL #203 | Ormond Beach | Florida |
| United States | CIL #191 | Overland Park | Kansas |
| United States | CIL #178 | Philadelphia | Pennsylvania |
| United States | CIL #189 | Phoenix | Arizona |
| United States | CIL #110 | Pinellas Park | Florida |
| United States | CIL #151 | Plano | Texas |
| United States | CIL #168 | Plano | Texas |
| United States | CIL #200 | Portland | Oregon |
| United States | CIL #194 | Richmond | Kentucky |
| United States | CIL #108 | Rochester | New York |
| United States | CIL #190 | Sacramento | California |
| United States | CIL #187 | Saint Louis | Missouri |
| United States | CIL #176 | Saint Petersburg | Florida |
| United States | CIL #221 | Salisbury | North Carolina |
| United States | CIL #106 | Salt Lake City | Utah |
| United States | CIL #224 | San Antonio | Texas |
| United States | CIL #113 | San Diego | California |
| United States | CIL #161 | San Diego | California |
| United States | CIL #227 | Sanford | Florida |
| United States | CIL #195 | Santa Ana | California |
| United States | CIL #119 | Santa Monica | California |
| United States | CIL #199 | Santa Rosa | California |
| United States | CIL #143 | Savannah | Georgia |
| United States | CIL #211 | South Miami | Florida |
| United States | CIL #144 | Tampa | Florida |
| United States | CIL #152 | Tampa | Florida |
| United States | CIL #229 | Tampa | Florida |
| United States | CIL #153 | Wellington | Florida |
| United States | CIL #215 | Wichita | Kansas |
| Lead Sponsor | Collaborator |
|---|---|
| Novan, Inc. | Chiltern International Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Subjects With Adverse Events Ongoing From Parent Study at Start of Study NI-AC303) | This outcome measure shows the number of subjects with at least one ongoing adverse event from the pivotal studies (NI-AC301 and NI-AC302) at the time they rolled over into this study (NI-AC303). The final study visit (Week 12) for the pivotal studies served as the Baseline visit for this study. Subjects who were assigned to SB204 in the pivotal studies are denoted as SB204 Experienced and subjects who were assigned to Vehicle Gel on the pivotal studies are denoted as SB204 Naive. | Baseline | |
| Primary | Number of Subjects With Treatment Emergent Adverse Events | Number of subjects with adverse events that had an onset date on or after entry into study NI-AC303. | Week 40/End of Treatment | |
| Secondary | Tolerability Assessment (Analysis of Tolerability Scores at Each Visit Through End of Treatment) | Analysis of cutaneous tolerability scores at each visit through end of treatment. Baseline is the Week 12 assessment from the previous study (NI-AC301 or NI-AC302). The Cutaneous Tolerability Assessment scale consisted of the investigator's assessment of erythema, scaling, and dryness at the time the assessment was made. Pruritus and burning/stinging were based on the subject's report for the previous 24 hours. Each component was graded on a scale of 0-3, with 0 being none (not present) and 3 being severe. Higher scores indicated a higher severity of reaction. | Baseline, Week 4, Week 12, Week 24, Week 36, Week 40 | |
| Secondary | Inflammatory Lesion Counts by Study Visit | Absolute count of inflammatory lesions at each visit (face only)--safety population | Baseline through Week 40 | |
| Secondary | Non-Inflammatory Lesion Counts by Study Visit | Absolute count of non-inflammatory lesions by study visit (face only) | Baseline through Week 40 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
| Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
| Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
| Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
| Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
| Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
| Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
| Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
| Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
| Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
| Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
| Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
| Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
| Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
| Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
| Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
| Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
| Completed |
NCT01706250 -
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
|
Phase 4 | |
| Completed |
NCT02524665 -
8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne
|
Phase 4 |